You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vascular Disrupting Agent

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Metastatic Trial in Australia (Nivolumab 10 MG/ML, BNC 105, BBI608)

Completed
  • Colorectal Cancer Metastatic
  • Nivolumab 10 MG/ML
  • +2 more
  • Albury, New South Wales, Australia
  • +13 more
Aug 26, 2021

Dilated Cardiomyopathy Trial in Kraków (Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent

Not yet recruiting
  • Dilated Cardiomyopathy
  • Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter
  • Kraków, Maloplska, Poland
    Department of Cardiac and Vascular Diseases, John Paul II Hospit
Aug 10, 2022

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Using TSPO

Recruiting
  • Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
  • PET Tracer
  • +2 more
  • New York, New York
    NYU Langone Health
Nov 7, 2022

Venous Insufficiency Trial in United States (ClariVein RES, Sodium Tetradecyl Sulfate 1% Injection, Sodium Tetradecyl Sulfate 3%

Terminated
Has Results
  • Venous Insufficiency
  • ClariVein RES
  • +2 more
  • Darien, Connecticut
  • +4 more
Feb 9, 2022

In-Stent Restenosis Trial in United States (AGENT DCB, PTCA balloon catheter)

Recruiting
  • In-Stent Restenosis
  • AGENT DCB
  • PTCA balloon catheter
  • Birmingham, Alabama
  • +39 more
Jul 21, 2022

Takotsubo Cardiomyopathy Trial (Metoprolol Injection, Saline)

Completed
  • Takotsubo Cardiomyopathy
  • (no location specified)
Mar 3, 2023

NSCLC Metastatic Trial in La Jolla (Nivolumab + Plinabulin)

Active, not recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Nivolumab + Plinabulin
  • La Jolla, California
    UC San Diego Moores Cancer Center
Nov 21, 2022

Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy Trial in Berkeley (Mail-in Urine Test for EDCs)

Completed
  • Endocrine Disrupting Chemicals
  • +5 more
  • Mail-in Urine Test for EDCs
  • Berkeley, California
    Million Marker Wellness Inc.
Mar 22, 2023

Ovarian Tumors, Tumors, Ovarian, Ovarian Cancer Trial in United Kingdom (Pazopanib, Fosbretabulin)

Terminated
  • Ovarian Neoplasms
  • +2 more
  • Bath, United Kingdom
  • +9 more
May 13, 2021

Unresectable Pancreatic Cancer Trial in Baltimore (NanoKnife IRE System)

Active, not recruiting
  • Unresectable Pancreatic Cancer
  • NanoKnife IRE System
  • Baltimore, Maryland
    University of Maryland Medical Center
Jan 30, 2023

Patients Treated With PuraBond Haemostatic Agent During

Recruiting
  • Hemostatic
  • Purabond
  • Milano, Italy
    IRCCS San Raffaele Hospital
Feb 21, 2023

Clear-cell Metastatic Renal Cell Carcinoma Trial in Worldwide (Everolimus, MLN0128, MLN1117)

Completed
Has Results
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Los Angeles, California
  • +35 more
Nov 18, 2021

Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent

Completed
  • Dural Arteriovenous Fistula
  • Squid
  • Augsburg, Germany
  • +6 more
Oct 8, 2020

Automated Carbon Dioxide Angiography in Fenestrated/Branched

Not yet recruiting
  • Thoracoabdominal Aortic Aneurysm
  • CO2 angiography
  • (no location specified)
Oct 24, 2023

NSCLC Trial in Japan (ASA404)

Completed
  • Non-small Cell Lung Cancer
  • Aichi, Japan
  • +3 more
Dec 6, 2020

PTSD, Cardiovascular Diseases, Autonomic Dysfunction Trial in Aurora, Denver (NightWare, Sham NightWare)

Recruiting
  • Posttraumatic Stress Disorder
  • +5 more
  • NightWare
  • Sham NightWare
  • Aurora, Colorado
  • +1 more
Dec 13, 2022

Diabetes, Type 2 Trial in Basel (Dapansutrile, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Basel, Switzerland
    University Hospital Basel
Sep 21, 2023

Covid19 Trial in Saint Louis Park, Saint Paul (Colchicine 0.6 mg, Naltrexone)

Completed
  • Covid19
  • Saint Louis Park, Minnesota
  • +1 more
Jan 10, 2023

During Systemic Agent Therapy in Psoriasis

Completed
  • Psoriasis
    • Chicago, Illinois
      Northwestern University, Department of Dermatology
    Jan 10, 2022

    Hemodynamic Stability Trial in Assiut (Bupivacaine 0.5% Injectable Solution, Prilocaine Hydrochloride 2% Injection)

    Recruiting
    • Hemodynamic Stability
    • Bupivacaine 0.5% Injectable Solution
    • Prilocaine Hydrochloride 2% Injection
    • Assiut, Assuit, Egypt
      Assuit university
    May 17, 2023

    Environmental Endocrine Disrupting Chemicals and Female

    Recruiting
    • IVF
    • there is no intervention in the study
    • Beijing, Beijing, China
      Peking University People's Hospital
    May 12, 2022

    Interleukin-6 Inhibition on Vascular, Endothelial and Left

    Unknown status
    • Rheumatoid Arthritis
    • Inflammation
    • Tocilizumab (Actemra®)
    • +2 more
    • Athens, Haidari, Greece
      Attikon Hospital
    Apr 1, 2020

    Childhood Brain Tumor, Recurrent Childhood Brain Tumor Trial in Portland (Dynamic Contrast-Enhanced Magnetic Resonance Imaging,

    Completed
    Has Results
    • Childhood Brain Neoplasm
    • Recurrent Childhood Brain Neoplasm
    • Dynamic Contrast-Enhanced Magnetic Resonance Imaging
    • +3 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jul 11, 2022

    Percutaneous Coronary Intervention, Pan-vascular Interventional Robotic System Trial in Kashgar (Pan-vascular interventional

    Not yet recruiting
    • Percutaneous Coronary Intervention
    • Pan-vascular Interventional Robotic System
    • Pan-vascular interventional robotic system
    • Kashgar, Xinjiang, China
      Kashi Prefecture Second People's Hospital
    Oct 30, 2023

    Coronary Artery Disease Trial in Japan (Device: Paclitaxel-Coated PTCA Balloon Catheter, SeQuent Please Drug Eluting Balloon

    Active, not recruiting
    Has Results
    • Coronary Artery Disease
    • Device: Paclitaxel-Coated PTCA Balloon Catheter
    • SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
    • Kitakyushu, Fukuoka, Japan
    • +13 more
    Dec 2, 2022